1
|
Xue Y, Chen T, Hou N, Wu X, Kong W, Huang J, Zhang J, Chen Y, Zheng J, Zhai W, Xue W. Serum extracellular vesicles derived hsa-miR-320d as an indicator for progression of clear cell renal cell carcinoma. Discov Oncol 2023; 14:114. [PMID: 37380801 DOI: 10.1007/s12672-023-00730-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2023] [Accepted: 06/15/2023] [Indexed: 06/30/2023] Open
Abstract
BACKGROUND Renal cell carcinoma (RCC) is a prevalent malignancy with a rising incidence in developing countries. Clear cell renal cell carcinoma (ccRCC) constitutes 70% of RCC cases and is prone to metastasis and recurrence, yet lacks a liquid biomarker for surveillance. Extracellular vesicles (EVs) have shown promise as biomarkers in various malignancies. In this study, we investigated the potential of serum EV-derived miRNAs as a biomarker for ccRCC metastasis and recurrence. MATERIALS AND METHODS Patients diagnosed with ccRCC between 2017 and 2020 were recruited in this study. In the discovery phase, high throughput small RNA sequencing was used to analyze RNA extracted from serum EVs derived from localized ccRCC (LccRCC) and advanced ccRCC (AccRCC). In the validation phase, qPCR was employed for quantitative detection of candidate biomarkers. Migration and invasion assays were performed on ccRCC cell line OSRC2. RESULTS Serum EVs derived hsa-miR-320d was significantly up-regulated in patients with AccRCC than in patients with LccRCC (p < 0.01). In addition, Serum EVs derived hsa-miR-320d was also significantly up-regulated in patients who experienced recurrence or metastasis (p < 0.01). Besides, hsa-miR-320d enhances the pro-metastatic phenotype of ccRCC cells in vitro. CONCLUSIONS Serum EVs derived hsa-miR-320d as a liquid biomarker exhibits significant potential for identifying the recurrence or metastasis of ccRCC, as well as hsa-miR-320d promotes ccRCC cells migration and invasion.
Collapse
Affiliation(s)
- Yizheng Xue
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160# Pu Jian Ave, Shanghai, 200127, China
| | - Tianyi Chen
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160# Pu Jian Ave, Shanghai, 200127, China
| | - Naiqiao Hou
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160# Pu Jian Ave, Shanghai, 200127, China
| | - Xiaorong Wu
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160# Pu Jian Ave, Shanghai, 200127, China
| | - Wen Kong
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160# Pu Jian Ave, Shanghai, 200127, China
| | - Jiwei Huang
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160# Pu Jian Ave, Shanghai, 200127, China
| | - Jin Zhang
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160# Pu Jian Ave, Shanghai, 200127, China
| | - Yonghui Chen
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160# Pu Jian Ave, Shanghai, 200127, China
| | - Junhua Zheng
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160# Pu Jian Ave, Shanghai, 200127, China
| | - Wei Zhai
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160# Pu Jian Ave, Shanghai, 200127, China.
- State Key Laboratory of Oncogenes and Related Genes, Department of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, 200127, China.
| | - Wei Xue
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160# Pu Jian Ave, Shanghai, 200127, China.
| |
Collapse
|